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Many cell membrane receptors, such as the nicotinic ace- 
tylcholine receptor and the T cell antigen receptor, are 
composed of several different subunits, and their correct 
assembly is necessary for the generation of functional re- 
ceptors. Most lymphokine receptors are composed of at 
least two components, and ligand-induced oligomeriza- 
tion is essential for receptor activation and signal transmis- 
sion. In recent years, it has become clear that various 
growth factors and lymphokines can bind to two different 
classes of cell surface receptors. For example, fibroblast 
growth factor (FGF) and transforming growth factor p 
(TGFB) both bind with high affinity to signaling receptors 
endowed with tyrosine or serinelthreonine kinase activi- 
ties. However, the same growth factors also bind with 
lower affinity to cell surface proteoglycans that cannot 
transmit signals alone, but somehow modulate the ability 
of the growth factor or the signaling receptor to generate 
a biological response (Klagsbrun and Baird, 1991; L6pez- 
Casillas et al., 1993; Yayon et al., 1991; Roghani et al., 
1994). 
Proteoglycans are proteins that are found predomi- 
nantly on the cell surface and in the extracellular matrix 
and that contain carbohydrates called glycosaminogly- 
cans. Glycosaminoglycans are polymers of disaccharide 
repeats, which are mostly highly sulfated and negatively 
charged. The main glycosaminoglycans in proteoglycans 
are chondroitin sulfate, dermatan sulfate, heparan sulfate, 
heparin, and keratan sulfate (Ruoslahti, 1989). Binding 
of growth factors to proteoglycans is thought to have an 
important regulatory role (Ruoslahti and Yamaguchi, 
1991). This has been particularly well explored for FGF, in 
which it has been shown that heparins (or heparan sulfate 
proteoglycans) are necessary for FGF-induced biologic&l 
responses (Mason, 1994). Several mechanisms have 
been proposed for the role of heparin. One such proposal 
is that proteoglycans stabilize FGF and protect it from pro- 
teolytic degradation, thus enhancing its efficacy. Another 
is that FGF bound to cell matrix proteoglycans serves as 
a reservoir of growth factors that can be released by en- 
zymes that degrade the proteoglycans (Saksela and Rif- 
kin, 1990). Several studies have also led to the proposal 
that binding to proteoglycans induces a conformational 
change in FGF that enhances its affinity for the signaling 
receptors (Yayon et al., 1991). However, other studies 
have shown that heparins can also interfere with FGF- 
induced mitogenic signaling (Mali et al., 1993), which is 
difficult to reconcile with the model proposing a conforma- 
tional change induced in FGF by heparin binding. A dual 
receptor model has been proposed, in which binding of 
FGF to low affinity cell surface proteoglycan receptors is 
required for the presentation of FGF molecules to their 
high affinity signaling receptors, which in turn transmit 
signals across the plasma membrane (Klagsbrun and 
Baird, 1991). A similar mechanism is suggested for other 
pairs of low and high affinity receptors, such as TGFB 
binding to the nonsignaling betaglycan receptor and to 
the two signaling receptors with serinelthreonine kinase 
activity(Lbpez-Casillas et al., 1993); neurotrophin binding 
to ~75 (low affinity) and to the various nerve growth factor 
(NGF) receptor tyrosine kinases (trkA, trkB, and trkC, 
which are high affinity), as well as the binding of the insulin- 
like growth factor IGF2 to the IGF2 receptor (nonsignaling 
receptor) and to the IGFl receptor (a receptor tyrosine 
kinase related to the insulin receptor). The existence of 
nonsignaling as well as signaling receptors for the same 
ligand is a feature common for many growth factors. How- 
ever, the physiological role of the nonsignaling receptors 
is poorly understood. 
The most discussed model for the role of the low affinity 
nonsignaling receptors is that they present the ligand to 
high affinity signaling receptors. Binding of the ligand to 
the high affinity signaling receptors will then activate this 
receptor and trigger biological responses. However, when 
a given ligand at low concentration is allowed to bind to 
cells that display on their surface both low and high affinity 
receptors, the law of mass action dictates that at equilib- 
rium the ligand will bind, predominantly, to high affinity 
receptors rather than to the low affinity receptors. This 
fact makes it difficult to accept the so-called presentation 
model. At higher ligand concentration, both the high and 
low affinity receptors will be occupied. The binding con- 
stants of the high affinity receptors are usually lo- to 1 OO- 
fold higher than those of the low affinity receptors. There- 
fore, even when the density of the low affinity receptors 
on the cell surface is higher by an order of magnitude, a 
similar number of high and low affinity receptors will be 
occupied upon saturation of the high affinity receptors. 
These arguments demonstrate the need for a different 
model to understand the role of the low affinity receptors. 
An alternative and more plausible model is that the primary 
function of these receptors is to reduce the dimensionality 
of ligand diffusion from three to two dimensions (Adam and 
Delbruck, 1968; Richter and Eigen, 1974). When ligands 
such as lymphokines or growth factors are bound to cell 
surface receptors, their diffusion is restricted to two dimen- 
sions ratherthan diffusing in thethree-dimensionalvolume 
of the extracellular space. Once restricted to just two di- 
mensions, the ligand molecules are more likely to encoun- 
ter and bind to the less abundant high affinity signaling 
receptors. In otherwords, binding of ligands, such as FGF, 
to abundant low affinity receptors that are restricted to 
two dimensions will increase the local concentration of the 
bound ligands at the plasma membrane, and the probabil- 
ity of their interaction with a high affinity receptor will be 
greatly enhanced. For example, 20,000 receptors per cell 
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Figure 1. Electrostatic Potential at the Surface of FGFl and FGF2 
Blue indicates positive potential, and red indicates negative electro- 
static potential. The top panel depicts a complex between FGFl (acidic 
FGF) and the heparin analog sucrose octasulfate (yellow) bound to 
the positively charged region on FGFl. The bottom panel shows the 
three dimensional structure and electrostatic potential of FGF2 (basic 
FGF). The figures were generated by the program GRASP (Nicholls 
and Honig, 1991). The electrostatic potential was calculated for uncom- 
plexed FGFl and is contoured at *2 kT. The potential for FGF2 is 
contoured at f 2.5 kT (Zhu et al., 1991, 1993). 
would correspond to an apparent molar concentration of 
approximately 1O-6 M. Interaction with low affinity recep- 
tors can also provide the ligands with important kinetic 
advantages. Let us consider the case of the FGFs. He- 
paran sulfate proteoglycans that serve as low affinity re- 
ceptors for FGFs are negatively charged molecules, while 
FGFl is markedly electrostatically polarized and FGF2 is 
highly positively charged (Figure 1). Binding of FGFs to 
heparan sulfate proteoglycanson the cell surface is, there- 
fore, likely to occur with a very high association rate. In- 
deed, it has been shown that the rate of reactions con- 
trolled by such electrostatic attraction can exceed the rate 
of a diffusion-limited bimolecular reaction (Sharp et al., 
1987). Once bound to the low affinity receptors, FGF mole- 
cules will exhibit rapid lateral mobility, since most surface 
receptors diffuse in the plasma membrane with apparent 
diffusion coefficients of 1 O-g to lo-lo cm2 per second. This 
lateral mobility will allow frequent encounters between the 
signaling 
receptor 
surface proteoglycan 
low-affinity receptors 
signaling 
receptor 
Figure 2. A Model for the Effect of Reduced FGF Dimensionality on 
Binding to the High Affinity Signaling FGF Receptors 
The electrostatistically polarized or basic FGF molecules (blue) bind 
with rapid on rates to the negatively charged cell surface heparan 
sulfate proteoglycans (red). Once restricted to two dimensions, the 
probability of the FGF molecules interacting with the high affinity sig 
naling FGF receptors is greatly increased. The rapid association and 
dissociation rates of FGF from the surface proteoglycan in the vicinity 
of the high affinity receptors will allow the formation of a stable complex 
with the signaling receptor (arrow with solid line). It should be noted 
that the binding sites on FGF for heparan sulfate proteoglycans and 
for the signaling receptors are distinct. Dissociation from the proteogly- 
can is therefore not required for interaction of FGF with the high affinity 
signaling receptors, Reduced dimensionality will also augment forma- 
tion of the ternary complex shown in Figure 3. The right-hand part of 
the schematic shows the much less efficient process of direct binding 
of FGF to the high affinity receptor (arrow with broken line), which 
does not take advantage of the increased efficiency offered by reduced 
dimensionality. 
occupied high density low affinity receptors and the unoc- 
cupied, less abundant high affinity receptors (Figure 2). 
Moreover, the low affinity receptors, to which association 
rates are very high, also exhibit high dissociation rates for 
the bound ligand, while the high affinities of the signaling 
receptors are usually determined by their slow off rates. 
It is therefore probable that dissociation from a low affinity 
receptor in the vicinity of high affinity receptors will lead 
to formation of the more stable complex with the signaling 
receptor (Figure 2). This is essentially a variation on the 
proposal mentioned above that proteoglycans serve as 
a reservoir of growth factors. However, both kinetic and 
thermodynamic considerations make it clear that an enzy- 
matic degradation event is not necessary for ligand bind- 
ing to the high affinity receptor. A major advantage of this 
organization is that the on rate for ligand binding to low 
affinity receptors can be very rapid (Tartaglia et al., 1993). 
The higher affinity of the signaling receptor negates any 
need for a presentation event. In fact, as shown in Figure 
3, dissociation from the low affinity receptors is not neces- 
sarily required for ligand binding to the signaling receptor. 
Reduced dimensionality will also augment formation of a 
ternary complex. 
In addition to accelerating the arrival of ligands at their 
high affinity receptors, proteoglycans can play an im- 
portant role in activation of the signaling receptor. This is 
particularly apparent in the case of the FGFs. It is now well 
established that growth factors and lymphokines activate 
their specific receptors by inducing receptor dimerization 
or oligomerization (Lemmon and Schlessinger, 1994). For 
example, biophysical and structural studies have demon- 
Minireview 
359 
Proteoglycan 
FGF 
inactive active 
Figure 3. A General Scheme for the Activation of FGF Receptor by 
Interaction with Multimeric FGF-Heparin Sulfate Proteoglycan 
Complex 
A cell surface proteoglycan molecule binds simultaneously to several 
FGF molecules, which in turn bind to the signaling FGF receptor with 
higher avidity as compared with monomeric FGF. Multivalent binding 
of the multimeric FGF complex stimulates FGF receptor dimerization 
and activation. P, phosphorylated tyrosine residue. 
strated that a single growth hormone molecule bridges two 
growth hormone receptor molecules and thus stabilizes 
receptor homodimers. Other cytokines, such as platelet- 
derived growth factor (PDGF), Steel factor, and inter- 
feron-y are homodimers themselves, and receptor dimer- 
ization is mediated by binding of a dimeric cytokine to two 
receptor molecules. FGFl and FGF2 can also induce FGF 
receptor dimerization and activation when added to intact 
cells, in spite of the fact that the stoichiometry of mono- 
meric FGF binding to the isolated extracellular domain of 
FGF receptor is 1:i (Spivak-Kroizman et al., 1994). It has 
been shown that FGF receptor dimerization is induced by 
multivalent binding of an FGF-heparin complex (Figure 
3). In the absence of either free heparin sulfate or cell 
surface heparan sulfate proteoglycans, FGF is unable to 
induce FGF receptor dimerization and activation. Several 
FGF molecules bind to a single heparan sulfate molecule 
(Ornitz et al., 1992), and the resulting multivalent FGF- 
heparan sulfate complex binds to the cell surface FGF 
receptor with higher avidity as compared with monomeric 
FGF (Figure 3). This is the most likely explanation for the 
plethora of studies showing an effect of heparin on FGF 
binding affinity (Yayon et al., 1991; Roghani et al., 1994; 
Mason, 1994). Formation of the multivalent complex is 
necessary for promoting receptor dimerization and activa- 
tion (Figure 3). 
Thus, in the case of FGF and its interaction with high 
affinity signaling receptors, the surface proteoglycan pro- 
vides at least two important functions. First, by binding 
to the more abundant low affinity receptors, the effect of 
reduced dimensionality for FGF will allow more frequent 
encounters with the high affinity signaling receptor (see 
Figure 2). Second, in the case of FGF, formation of a 
multivalent FGF-proteoglycan complex is required for 
FGF-induced dimerization of the signaling receptors (Fig- 
ure 3). It is noteworthy that, when free heparan sulfate is 
present at large molar excess over FGF, every growth 
factor molecule will bind to a single heparan sulfate mole- 
cule. Under these conditions, the FGF-heparan sulfate 
complex will be monovalent, so heparan sulfate may an- 
tagonize the action of FGF by preventing receptor dimer- 
ization. Thus, the notion that heparan sulfate proteogly- 
cans act as accessory proteins that regulate FGF 
oligomerization offers a molecular mechanism for both the 
activating and inhibitory effects of heparins on FGF- 
induced mitogenesis (Mason, 1994). 
Heparin may not be important for oligomerization of all 
heparin-binding growth factors. Growth factors such as 
vascular endothelial growth factor and heparin-binding 
epidermal growth factor (EG F) may induce receptor dimer- 
ization in the absence of soluble heparin or cell surface 
proteoglycans. Furthermore, it has been demonstrated 
that TGFB binds to the protein core of betaglycan and 
that the low affinity receptor is probably not required for 
TGFP-induced dimerization of the two signaling receptors 
TGFpRl and TGF(3R2. In these cases, the main effect of 
the low affinity receptors may be to provide the advantages 
of directed reduction of ligand dimensionality. The low af- 
finity receptors will attract ligand molecules to the cell sur- 
face with rapid kinetics and effectively “funnel” them to 
the less abundant high affinity receptors. This process 
could be viewed as analogous to the nonspecific attraction 
of /ac repressor to molecules of DNA. Diffusion of the lac 
repressor is then restricted to one dimension, and it 
“slides” along the DNA until it reaches a specific high affin- 
ity /ac operator recognition site (Richter and Eigen, 1974; 
Berg et al., 1981). 
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